NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a best efforts offering. All of the securities to be sold in the offering are to be offered by Eyenovia.

2024年8月20日，纽约（环球通讯社）--商业舞台眼科公司Eyenovia，Inc.（“Eyenovia”或“公司”）（纳斯达克：EYEN）今天宣布，它打算以最大努力的方式发行和出售其普通股（或预先出资的认股权证代替）的股票。此次发行中出售的所有证券都将由Eyenovia提供。

The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering (the 'Offering'). The Company intends to use the net proceeds from this Offering to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes, which may include the repayment of a portion of existing indebtedness.

本次发行受市场条件制约，无法保证是否或何时完成本次发行，也无法保证本次发行的实际规模或条款（“发行”）。。

Dawson James Securities, Inc. is the sole placement agent for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-261638), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 14, 2021, and declared effective on December 23, 2021.

道森詹姆斯证券有限公司是此次发售的唯一配售代理。此次发售是根据表S-3（文件号333-261638）上的货架登记声明进行的，包括一份基本招股说明书，于2021年12月14日提交给美国证券交易委员会（“SEC”），并于2021年12月23日宣布生效。

The offering will be made only by means of a prospectus supplement and accompanying prospectus. The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

本次发行将仅通过补充招股说明书和随附招股说明书的方式进行。初步补充招股说明书和描述拟议发售条款的随附招股说明书将提交给美国证券交易委员会，并可在美国证券交易委员会的网站上查阅http://www.sec.gov.

Electronic copies of the preliminary prospectus supplement may be obtained, when available, from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432 or by telephone at (561) 391-5555, or by email at investmentbanking@.

初步补充招股说明书的电子副本可从道森詹姆斯证券有限公司（地址：101 North Federal Highway，Suite 600，Boca Raton，FL 33432）或电话（561）391-5555或电子邮件investmentbanking@.